Your browser doesn't support javascript.
loading
CRISPR RNAs trigger innate immune responses in human cells.
Kim, Sojung; Koo, Taeyoung; Jee, Hyeon-Gun; Cho, Hee-Yeon; Lee, Gyeorae; Lim, Dong-Gyun; Shin, Hyoung Shik; Kim, Jin-Soo.
Afiliación
  • Kim S; Center for Genome Engineering, Institute for Basic Science, Seoul 08826, South Korea.
  • Koo T; Center for Genome Engineering, Institute for Basic Science, Seoul 08826, South Korea.
  • Jee HG; Department of Basic Science, University of Science & Technology, Daejeon 34113, South Korea.
  • Cho HY; Center for Chronic Diseases, Research Institute, National Medical Center, Seoul 04564, South Korea.
  • Lee G; Center for Genome Engineering, Institute for Basic Science, Seoul 08826, South Korea.
  • Lim DG; Center for Genome Engineering, Institute for Basic Science, Seoul 08826, South Korea.
  • Shin HS; Department of Basic Science, University of Science & Technology, Daejeon 34113, South Korea.
  • Kim JS; Center for Chronic Diseases, Research Institute, National Medical Center, Seoul 04564, South Korea.
Genome Res ; 2018 02 22.
Article en En | MEDLINE | ID: mdl-29472270
ABSTRACT
Here, we report that CRISPR guide RNAs (gRNAs) with a 5'-triphosphate group (5'-ppp gRNAs) produced via in vitro transcription trigger RNA-sensing innate immune responses in human and murine cells, leading to cytotoxicity. 5'-ppp gRNAs in the cytosol are recognized by DDX58, which in turn activates type I interferon responses, causing up to ∼80% cell death. We show that the triphosphate group can be removed by a phosphatase in vitro and that the resulting 5'-hydroxyl gRNAs in complex with Cas9 or Cpf1 avoid innate immune responses and can achieve targeted mutagenesis at a frequency of 95% in primary human CD4+ T cells. These results are in line with previous findings that chemically synthesized sgRNAs with a 5'-hydroxyl group are much more efficient than in vitro-transcribed (IVT) sgRNAs in human and other mammalian cells. The phosphatase treatment of IVT sgRNAs is a cost-effective method for making highly active sgRNAs, avoiding innate immune responses in human cells.